click enter text
best posit tool confirm
diagnost key commentari manag call came
morn call convinc estim fair
conserv evid acceler test demand bioproduct trial
servic momentum hospit ppe demand tmo think least direct
line dx opportun see expect demand
outstrip grow product volum approach
time tmo guid tailwind mol dx align close
view pcr market upsid increment vs
test model respect bull case management clarifi
vast major test run hardwar latest consult
dilig confirm best posit rel covid test econom
scale kit produc well distribut avail capac
covid headwinds/tailwind covid-driven revenu
headwind analyt instrument segment difficulti
instal instrument china given china exposur over-index
hardwar semi wuhan top-lin impact hit life
scienc came lp spec dx gave
rang potenti headwind lockdown scenario base
length lockdown us/eu end market china notabl back
normal present sens print flat lockdown unwind
start end april test uptak continu ramp
result comment support framework affirm
appeal mdx player interact model likelihood sharp
hardwar pressur summer tmo hardwar bp tougher
forecast rest busi broadli stronger reinforc
acceler bifurc evid result yesterday lab outlook
sharpli reduc off-set bioprocess strength vaccine/apac pull-
forward guid addit debt accru acq reduc interest
incom drive cut ep balanc rais pt
key learn re-affirmed deal close time
expect posit collabor regulatori approv process pharma
end market insul covid relat pressur academ
suppress closur expect rapid re-ramp independ univers re-
open expect supplementari fund materi suppli chain
disrupt note date
trade fundament data
upsid target
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
result wolf model chang
exhibit annual quarterli guidanc tracker
exhibit premium multipl
page
mncurrent qconsensusorgan impactestimatevarianceanalyt bp life organ bpslaboratori product organ bpsspecialti organ excl adj incom incom net incom share estimate annual guidanc margin flat gm margin tax ep dilut sale dilut sale dil share share done net quarterli wolf researchguid wolf price-to-earnings premium price-to-earnings
note tailwind/headwind segment extrapol headwind fall ai ls apiec lp spec dx tailwind fall
lss lp spec dx
note exposur framework slide reason
note exposur framework slide reason
exhibit look insul base favor
exposur group
posit back half return academ non
note exposur framework slide reason
note exposur framework slide reason
page
model actual/estcovid headwindscovid tailwindsimpli underlyingimpli momentumcategori ex ex ex excl adj quarterli impact total saleslockdown macro impact salesweek lockdownest exit org covid co impli covid/macro headwind vs impli risk current org growth impli total
note base busi exclud growth fei pthn bioprocess bioscienc sub-divis
page
page
page
yieldfcf compound-annual-growth-rate ebitda compound-annual-growth-rate ev-ebitda vs estimate ebitda compound-annual-growth-rate tool price-to-earnings premium compound-annual-growth-rate price-to-earnings premium tool median median median
note figur million unless state per-shar term
page
excl deal relat share fulli ebit increment
note figur million unless state per-shar term
page
